B-cell acute lymphoblastic leukemia: treatment phases and what MRD means

The results that shape the first plan

B-cell ALL begins in immature lymphoid cells. A blood count alone does not provide the full treatment picture. Bone marrow assessment, flow cytometry and genetic testing establish the diagnosis and identify features that influence the regimen. One important finding is BCR::ABL1, also called Philadelphia chromosome-positive ALL, which introduces targeted kinase inhibitors into treatment.

Age and fitness also matter. Children, adolescents, younger adults and older adults may follow different protocols. Ask which protocol applies to you and why. This article describes the treatment framework; the medicines and sequence should be written specifically for the person receiving care.

Sources and references: [1]

Induction aims to establish remission

The first intensive phase reduces the leukemia burden and allows healthy blood production to recover. Depending on the protocol, it can involve several chemotherapy medicines, targeted treatment or immunotherapy. Infection prevention, transfusions and treatment of metabolic complications may be as important as the anticancer medicines during these weeks.

Remission means the leukemia meets defined response criteria. It is the point from which further treatment proceeds. Ask when the marrow will be tested, what recovery is expected and which result would lead to a different plan.

Sources and references: [1]

Reading an MRD report

MRD testing uses more sensitive laboratory methods to look for a small remaining leukemia population. A report should identify the method, specimen, timing and detection limit. An MRD-negative result means the test did not detect leukemia at that level of sensitivity.

The same result can have different implications at different treatment milestones. Bring the original reports when seeking another opinion, especially if laboratories used different methods. Ask whether the result changes the planned consolidation, supports an immunotherapy approach or prompts discussion of transplant.

Sources and references: [2] [1]

Why treatment includes the brain and spinal cord

Leukemia cells can involve areas that some medicines reach less effectively. ALL protocols therefore include central nervous system prevention or treatment, often with medicines delivered into the spinal fluid and sometimes with systemic medicines that reach this area.

Lumbar punctures may continue even when blood counts and marrow look much better. Ask how this part of treatment fits into the calendar and what to report afterward. A severe or persistent headache, neurological changes or fever should be discussed promptly with the clinical team.

Sources and references: [1]

Treatment after remission

Consolidation aims to reduce remaining disease and relapse risk. Blinatumomab, a treatment that brings T cells into contact with CD19-positive leukemia cells, is included in some B-cell ALL plans. Evidence supports its use in selected patients even when MRD is already negative, so MRD positivity is not the only reason it may be discussed.

Other approaches depend on the leukemia's genetics and prior response. The relevant comparison is between complete protocols, including their supportive care and monitoring. Ask how the proposed next phase changes relapse risk and what additional hospital visits or monitoring it requires.

Sources and references: [1] [2]

When a donor transplant enters the discussion

An allogeneic transplant may be considered for selected higher-risk disease, persistent leukemia or relapse, depending on response and the available treatment options. MRD is one part of this decision. Organ function, previous complications and the risks of transplant itself also need careful review.

It can be useful to begin donor assessment while treatment continues, even before a final transplant decision. Ask what must happen before transplant becomes the preferred route and what the alternative plan would be if remission deepens with further treatment.

Sources and references: [1] [3]

Maintenance and care between treatment blocks

Some protocols include a prolonged maintenance phase. Treatment intensity may be lower, but taking medicines as prescribed and attending blood tests remain important. A written calendar helps families manage medication changes, laboratory appointments and contact with the treatment team.

Discuss work or school, infection precautions, fertility and vaccination planning at the appropriate points. During periods of low immunity, fever or sudden illness needs urgent assessment. Keep the emergency instructions accessible to the person who may accompany you to hospital.

Sources and references: [1]

Organizing a leukemia consultation in Shanghai

For a Shanghai review, prepare the diagnostic marrow report, flow cytometry, chromosome and molecular results, all MRD reports and the current protocol. Ruijin Hospital includes hematology in its international medical services. The receiving team can identify the appropriate adult service; children need a pediatric hematology pathway.

EastMedGo can help organize an inquiry around a specific question, such as persistent MRD or whether a transplant consultation is needed. We can clarify records, appointment logistics and coordination arrangements before travel. Acute leukemia care often has little room for delay, so a second consultation should fit the ongoing treatment plan.

Sources and references: [4] [1]

Common questions